Nurix Therapeutics (NRIX) Return on Sales (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Return on Sales data on file, last reported at 0.1% in Q2 2026.

• On a quarterly basis, Return on Sales fell 9.0% year-over-year to 0.1% in Q2 2026; TTM through May 2026 was 0.09%, a 7.0% decrease from a year earlier, with the FY2025 full-year figure at 0.03%, changed 0.0% from the prior year.
• Return on Sales for Q2 2026 stood at 0.1%, up from 0.14% in the prior quarter.
• Over the last five years, Return on Sales for NRIX reached as high as 0.01% in Q2 2023 and fell as low as 0.14% in Q1 2026.
• Historically, Return on Sales has averaged 0.05% across 5 years, with a median of 0.04% in 2024.
• Across the five-year window, Return on Sales advanced 4 bps in 2023 and slipped 11 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.07% in 2022, then jumped by 60 bps to 0.03% in 2023, then plunged by 59 bps to 0.04% in 2024, then tumbled by 31 bps to 0.06% in 2025, then tumbled by 72 bps to 0.1% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.1% in Q2 2026, 0.14% in Q1 2026, and 0.06% in Q4 2025.